The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Type 1 dendritic cells are key to initiate and maintain anti-tumoral T-cell responses in diverse tumour tissues. Our lab focuses on tissue-specific properties of cDC1 in lung tumours, focusing on the ...

While both are called medullary carcinoma, these cancers differ in many ways: ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Understanding the frequency of oncogenic variants in specific populations helps elucidate carcinogenesis and risk factors, with somatic variants often serving as treatment markers. Data regarding the ...

aCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA bDepartment of Pathology and Laboratory Medicine, University of Pennsylvania ...

Despite these concerns, the long-term oncogenic safety of autologous CAR T cells has been remarkably positive. More than two decades have passed since the first patients were infused with autologous ...

Several factors contribute to the RPSC RAS Cut Off 2024 for all the categories. However, these factors change every year. Some of these factors are listed below. Number of Test-Takers Categories ...